RecruitingNCT06314529
Long-term Follow-up Study of BHC001 for TDT
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
Sponsor
Bioray Laboratories
Enrollment
6 participants
Start Date
Dec 14, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility
Min Age: 5 YearsMax Age: 35 Years
Inclusion Criteria2
- Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERAssessments
Safety and efficacy assessments
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06314529
Related Trials
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT057364196 locations
Study of the Role of Genetic Modifiers in Hemoglobinopathies
NCT0579911826 locations
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
NCT060416201 location